MethylGene Inc.
TSX : MYG

MethylGene Inc.

April 12, 2006 08:00 ET

MethylGene Announces Annual Meeting of Shareholders

MONTREAL, QUEBEC--(CCNMatthews - April 12, 2006) - MethylGene Inc. (TSX:MYG), will hold its Annual General Meeting of Shareholders on Thursday April 20th, 2006 at 10:00 a.m. (EDT) at Fairmont The Queen Elizabeth Hotel, 900 Rene-Levesque Blvd. West, Montreal, Quebec. For those who are unable to attend in person, the presentation given during the meeting will be available by webcast on the Company's website at www.methylgene.com.

Mr. Donald F. Corcoran, MethylGene's President and Chief Executive Officer, will review the important events of the past year and present the Company's projected milestones for 2006.



WHAT: Annual General Meeting of Shareholders of MethylGene

WHERE: Fairmont The Queen Elizabeth Hotel
900 Rene-Levesque Blvd. West
Montreal, Quebec

WHEN: Thursday, April 20th 2006 at 10:00 a.m. (EDT)


About MethylGene

MethylGene is a publicly-traded biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics in cancer and infectious diseases. We intend to exploit our HDAC inhibitor technology in other diseases, such as diabetes, inflammation, fungal infections and neurodegenerative disorders. Two cancer product candidates are currently in clinical trials: MGCD0103, partnered with Pharmion Corporation and Taiho Pharmaceutical Co., Ltd., and MG98, partnered with MGI Pharma, Inc. MethylGene has an exclusive license agreement with Merck & Co. for the development and commercialization of small molecule beta-lactamase inhibitors to overcome antibiotic resistance. MethylGene has partnered its non-oncology HDAC program for neurodegenerative diseases with EnVivo Pharmaceuticals. MethylGene has a portfolio of preclinical programs for its multi-targeted kinase and histone deacetylase (HDAC) inhibitors for both oncology and non-oncology indications, and continues to seek partnering opportunities in these areas. Please visit our website at www.methylgene.com.

Certain statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, may constitute forward-looking statements. Such statements, based as they are on the current expectations of management of MethylGene, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond MethylGene's control. Such risks include, but are not limited to, the impact of general economic conditions, economic conditions in the pharmaceutical industry, changes in the regulatory environment in the jurisdictions in which MethylGene does business, stock market volatility, fluctuations in costs, expectations with respect to our intellectual property position and our ability to protect our intellectual property and operate our business without infringing upon the intellectual property rights of others, changes in the competitive landscape including changes in the standard of care for the various indications in which MethylGene is involved, and changes to the competitive environment due to consolidation, as well as other risks, which you are urged to read, as described in MethylGene's Annual Information Form for the fiscal year ending December 31, 2005, under the heading "risk factors," that can be found at www.SEDAR.com. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. The reader should not place undue reliance on the forward-looking statements included in this presentation. These statements speak only as an update on the date they are made and MethylGene is under no obligation to revise such statements as a result of any event, circumstance or otherwise except in accordance with law.

Contact Information

  • MethylGene Inc.
    Andrea Gilpin, Ph.D, MBA
    Director, Investor Relations & Project Management
    (514) 337-3333 ext. 416
    gilpina@methylgene.com